Trials / Completed
CompletedNCT02476123
Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors
Phase 1 Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 118 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to characterize the safety and tolerability and determine the maximum tolerated dose (MTD) or the recommended fixed dose of the combinations of Mogamulizumab and Nivolumab in subjects with locally advanced or metastatic solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558) | i.v. administration |
Timeline
- Start date
- 2015-06-01
- Primary completion
- 2018-02-07
- Completion
- 2018-12-21
- First posted
- 2015-06-19
- Last updated
- 2019-06-11
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02476123. Inclusion in this directory is not an endorsement.